Total Nutraceutical Solutions Licenses Pulsed UV Light Patent

Total Nutraceutical Solutions, Inc. has announced that the company has acquired from The Penn State Research Foundation (PSRF) an exclusive license agreement on the invention (the "Invention") entitled "Methods and Compositions for Improving the Nutritional Content of Mushrooms and Fungi." This invention is covered by the United States Patent Application No. 12/386,810, filed on April 23, 2009 and is also derived from U.S. Provisional Patent Application No. 61/047,268, filed on April 23, 2008, and names Robert Beelman and Michael Kalaras as co-inventors.

Pulsed UV light is a technology that delivers energy from light at a high peak power in a short amount of time. This technology results in the production by certain mushrooms of large amounts of Vitamin D2 within periods of time, varying from 1--30 seconds.

Vitamin D is a fat-soluble vitamin that has two major physiologic forms; vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is produced by mushrooms and plants in response to UV light. Vitamin D3 is produced in the skin by animals and humans also in response to UV light exposure. These 2 forms of Vitamin D have many physiologic roles including maintaining blood levels of phosphorus and calcium, promotion of bone mineralization and calcium absorption, maintaining a healthy immune system, and regulating cell differentiation and growth. Recent studies have also shown a link between vitamin D deficiency and diseases such as cancer, chronic heart disease, inflammatory bowel disease and even mental illness.

Vitamin D is essential for life and recent demographic studies have revealed that significant numbers of people in different countries are deficient in Vitamin D levels. The significance of Vitamin D to health is emphasized in a recently published review paper that stated that increasing the mean serum level of vitamin D above normal could reduce annual deaths in Canada by 16.1%. and decrease the economic health burden by 6.9% or $14.4 billion dollars less the cost of the program. (W.B. Grant et al, Mol.Nutr.Food Res.2010,54,1-10).

"The license of this invention propels TNS to the forefront of dietary supplement research and development," stated Marvin S. Hausman MD, CEO, TNS. "Our company will focus its efforts on naturally increasing Vitamin D2 levels in organically grown specific specialty mushrooms that contain the highest levels of key bionutrients and antioxidants. We are excited about the potential benefits of this technology to healthcare and towards that goal TNS has launched nutritional studies in well-known biologic models of oxidative stress and neurodegenerative diseases, such as Alzheimer's disease, with Vitamin D2 enriched mushrooms."

About Total Nutraceutical Solutions, Inc.

Total Nutraceutical Solutions, Inc., a global leader in mushroom research and development, focuses on discovering, formulating and marketing products composed primarily of organic natural whole mushroom foods, containing bioactive nutrients, such as L-Ergothioneine and Vitamin D, with potential health benefits. Our scientific strategy is to specialize in the development of production and analytic technologies for food and nutritional supplements mainly composed of mushrooms and their mycelial biomasses. Novel clinical models and biomarkers are used to show nutritional and clinical efficacy of our products. In addition to our novel preventative healthcare formulations and nutritional approaches for a wide variety of human conditions and illnesses, we are also involved in the development, acquisition and ownership of breakthrough nutritional tools and products in the fields of animal husbandry and livestock feeds.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc. with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2009 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.